ORYGEN Youth Health   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Melbourne Australia (1988)

Organization Overview

First Clinical Trial
2003
NCT00449397
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Orygen | ORYGEN Research Centre/ ORYGEN Youth Health | ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, | Orygen Youth Health Research Centre

Active Ingredients

Drugs in Phase 3 Trials (4)

fluoxetine (prozac) (1 trial)

icosapent ethyl (vascepa) (1 trial)

quetiapine (seroquel) (1 trial)

taurine (1 trial)

Drugs in Phase 2 Trials (1)

guanfacine (tenex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

22q11 Deletion Syndrome (Phase 3)

Disease (Phase 3)

Mental Disorders (Phase 3)

Personality Disorders (Phase 3)

Psychotic Disorders (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5